Exclusive: Moldova clears first gene editing study for HBV in humans

Lei Lei Wu

News Reporter

Precision Biosciences has received clearance from regulators in the Eastern European country of Moldova to begin a human trial of a gene editor for chronic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Moldova clears first gene editing study for HBV in humans

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Adults 50 and up should get pneumococcal vaccine, CDC advisors say, in boost to Pfizer and Merck

Novo Nordisk petitions FDA to stop semaglutide compounding over safety risks

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

GSK offers glimpse at RSV vaccine in at-risk younger adults before ACIP meeting

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ex­clu­sive: Moldo­va clears first gene edit­ing study for HBV in hu­mans

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Moldova clears first gene editing study for HBV in humans